Oncology

Significant advancements in tailoring salvage therapy for pediatric patients with relapsed or refractory classic Hodgkin lymphoma (cHL) have been revealed in a recent clinical trial.

A recent study has unveiled a mechanism by which estrogen receptor-positive (ER+) breast cancer cells become more aggressive after spreading to the bone marrow.

A recent Phase I clinical trial has provided promising results for a novel immunotherapy approach to treat early-stage ERBB2-positive breast cancer.

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).

A new AI-powered model predicts outcomes for breast cancer patients on CDK4/6 inhibitors, offering precise insights into treatment response and enabling personalized care.

In this study, patients with a recurrence scores greater than 31 exhibited significant improvements in survival outcomes when treated with taxane and anthracycline-based chemotherapy.